Rezolute's Rare Disease Drug Fails to Beat Placebo in Key Trial

Rezolute's ersodetug therapy for congenital hyperinsulinism failed Phase 3 trial, missing primary endpoints. Stock plunged 90% as the drug showed no significant advantage over placebo.